STudy to Assess Rapid Disease Progression by Clinical and Genetic Factors In Glaucoma patientS That Are High Risk

INCLUSION CRITERIA Subjects will be eligible if the following criteria are met: * Group A (diagnosis of primary open-angle glaucoma or pseudo-exfoliative glaucoma) - subjects with documented disease progression in the past 3 years and high IOP (IOP above target), disc hemorrhage (within 3 years), family history of glaucoma-related vision loss or thin central cornea (\<510um), * Progression is confirmed with repeatable abnormal standard automated perimetry (SAP) or progressive glaucomatous optic neuropathy * For patients that have had previous glaucoma surgery, they can be included if they have had documented glaucomatous progression post-surgery * Best corrected visual acuity of 20/40 or better at enrollment * Group B (healthy controls)- healthy subjects without any ophthalmic disease and an IOP \< 22mmHg o Normal appearing optic disc and no evidence of optic disc damage * Ability to provide written informed consent for participation in this study EXCLUSION CRITERIA Subjects who meet any of the following criteria will be excluded from this study: * Subjects with an ocular disease other than glaucoma * Subjects participating in a long-term interventional clinical trial * Subjects with any other medical condition which would prohibit them from making all study visits within the 24 months * Glaucoma patients who have not demonstrated disease progression in the past 3 years * Patients with diagnosis of pigmentary dispersion syndrome/glaucoma * Patients that have had glaucoma surgery and have IOP ≤ 12 mm Hg * Patients with advanced glaucoma with MD ≤ -20 dB * Patients with a history of LASIK surgery * Patients with myopia \> -6.0 diopters. * Patients with hyperopia \>+6.0 diopters. * In the investigator's opinion, any patient that cannot satisfactorily complete all of the structural and functional testing included in the protocol (investigator determined) * Unable to perform reliable VF testing (Fixation losses 33% or less, false negative rate 33% or less and false positive rate of 15% or less) at the time of study entry * In the investigator's opinion, any patient with an ocular disease that could impact study assessments * Patients with cataracts in which surgery is planned or anticipated within the next 3 months. * Patients with narrow angles in which laser iridotomy is planned or anticipated within the next 3 months.